We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+11.86%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$395M
AUM Growth
+$107M
Cap. Flow
+$91.9M
Cap. Flow %
23.24%
Top 10 Hldgs %
65.16%
Holding
37
New
10
Increased
12
Reduced
2
Closed
12

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$24.2M
2
INSP icon
Inspire Medical Systems
INSP
+$20.8M
3
ARGX icon
argenx
ARGX
+$17.8M
4
PFE icon
Pfizer
PFE
+$16.4M
5
ASND icon
Ascendis Pharma A/S
ASND
+$15.7M

Top Sells

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$19.9M
2
MRK icon
Merck
MRK
+$15.7M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
BAX icon
Baxter International
BAX
+$13.6M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARCT icon
26
Arcturus Therapeutics
ARCT
$164M
– –
-138,927
Closed -$4.69M
ARQT icon
27
Arcutis Biotherapeutics
ARQT
$3.36B
– –
-449,694
Closed -$4.46M
ATXS
28
DELISTED
Astria Therapeutics
ATXS
– –
-369,549
Closed -$5.2M
BAX icon
29
Baxter International
BAX
$13.5B
– –
-317,566
Closed -$13.6M
CATX icon
30
Perspective Therapeutics
CATX
$332M
– –
-78,030
Closed -$929K
EXAS
31
DELISTED
Exact Sciences
EXAS
– –
-90,000
Closed -$6.22M
LYRA
32
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-19,576
Closed -$6.09M
MRK icon
33
Merck
MRK
$322B
– –
-119,200
Closed -$15.7M
TNDM icon
34
Tandem Diabetes Care
TNDM
$1.34B
– –
-326,506
Closed -$11.6M
VRTX icon
35
Vertex Pharmaceuticals
VRTX
$121B
– –
-35,598
Closed -$14.9M
SILK
36
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-1,083,605
Closed -$19.9M
ALPN
37
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-120,687
Closed -$4.78M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Tri Locum Partners held 37 positions worth $395M, up 37% from $288M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Tri Locum Partners deployed $91.9M of net new capital in Q2 2024, opening 10 new positions and adding to 12 existing holdings. Its largest new stake was Amgen: 82,271 shares worth $25.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $4.22M trimmed.

  • Tri Locum Partners's largest Q2 2024 buy was Amgen: 82,271 shares worth $25.7M.
  • Tri Locum Partners added most to Inspire Medical Systems in Q2 2024, an estimated $20.8M increase.
  • Tri Locum Partners's biggest Q2 2024 reduction was Xenon Pharmaceuticals, cutting an estimated $4.22M.
  • Tri Locum Partners fully exited Silk Road Medical, Inc. Common Stock in Q2 2024, selling an estimated $19.9M.
  • Tri Locum Partners's ten largest holdings make up 65% of its $395M portfolio in Q2 2024.
  • Tri Locum Partners opened 10 new positions and closed 12 in Q2 2024.
  • Tri Locum Partners's portfolio value rose 37% quarter-over-quarter to $395M.

Based on Tri Locum Partners's 13F filing for Q2 2024, filed 14 Aug 2024.